Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
PHARMA JUMP CONSULTING from Liège, company number BE0688827286, closed financial year 2025 with a result of € -12,934 after tax. For that financial year PHARMA JUMP CONSULTING recorded a gross margin of € -2,780 and equity of € -7,761. Compared with financial year 2024, the result moved from € -13,427 to € -12,934. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ -7,761
▼ € 12,934 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12,934
▲ 4 % less loss than in 2024
Profit after tax over the fiscal year.
€ 3,298
▼ 88% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -26,361.
People and assets in 2025
€ 9,397
▼ 49% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 19,340
▲ € 14,725 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 12,102
▼ 36% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 6,074 | € 63,549 | € -3,589 | € -2,780 | ▲ € 809 |
| Profit after taxes | € 2,681 | € 42,993 | € -13,427 | € -12,934 | ▲ € 492 |
| Equity | € 38,478 | € 18,600 | € 5,173 | € -7,761 | ▼ € 12,934 |
| Total debts | € 13,645 | € 84,484 | € 71,042 | € 74,735 | ▲ 5% |
| Cash | € 19,643 | € 55,483 | € 27,748 | € 3,298 | ▼ 88% |
| Retained profit | € 19,878 | € 0 | € -13,427 | € -26,361 | ▼ € 12,934 |
| Dividend | € 0 | € 62,871 | € 0 | € 0 | |
| Balance sheet total | € 52,123 | € 103,084 | € 76,215 | € 66,973 | ▼ 12% |
Key figures of PHARMA JUMP CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA JUMP CONSULTING?
What happened at PHARMA JUMP CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 12,934. Source: NBB ↗
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,681 profit in 2022 to € 12,934 loss in 2025.
Paid € 13,536 in corporate taxes since 2022.
Best year ever: 2023, with € 42,993 profit.
Paid out € 62,871 in dividends to the owners in total.
A new publication or filing at PHARMA JUMP CONSULTING? We notify you, reason included.
Follow PHARMA JUMP CONSULTINGDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA JUMP CONSULTING are LAURENCE BOURGARD and Patrick JEUKENNE.
Directors
According to the 2025 annual accounts
LAURENCE BOURGARD
Director
Patrick JEUKENNE
Director
Establishments
Establishment units
Physical locations of this company
Avenue des Pâquerettes 2 box A
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0688.827.286
- VAT number
- BE 0688.827.286
- Registered office
- Avenue des Pâquerettes 2 bus A, 4000 Liège
- Names & denominations
- PHARMA JUMP CONSULTING
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 January 2018
- Peppol
- Active · Active since 24 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Overige vormen van onderwijs
Activiteiten van reclamebureaus
Vervaardiging van farmaceutische grondstoffen